3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Sell
1
HOOK Quote, Financials, Valuation and Earnings
Last price:
$1.81
Seasonality move
:
-6.53%
Day range:
$1.75 - $2.14
52-week range:
$1.75 - $10.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.44x
P/B ratio:
0.30x
Volume:
402.3K
Avg. volume:
186.5K
1-year change:
-76.73%
Market cap:
$21.5M
Revenue:
$20.1M
EPS (TTM):
-$3.71
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
$6.5M | -$0.69 | -32.32% | -55.71% | $16.33 |
|
BMRA
Biomerica
|
-- | -- | -- | -- | -- |
|
CDTX
Cidara Therapeutics
|
$240K | -$3.49 | -99.45% | -444.53% | $31.50 |
|
GILD
Gilead Sciences
|
$7.2B | $1.70 | 0.56% | 49.61% | $99.96 |
|
NBY
NovaBay Pharmaceuticals
|
$2.5M | -$0.24 | -60.77% | -99.16% | $7.30 |
|
PYXS
Pyxis Oncology
|
-- | -$0.33 | -100% | -1.73% | $8.83 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
$1.78 | $16.33 | $21.5M | -- | $0.00 | 0% | 0.44x |
|
BMRA
Biomerica
|
$0.32 | -- | $5.4M | -- | $0.00 | 0% | 0.98x |
|
CDTX
Cidara Therapeutics
|
$21.19 | $31.50 | $231.9M | -- | $0.00 | 0% | 1.74x |
|
GILD
Gilead Sciences
|
$89.94 | $99.96 | $112.1B | 999.33x | $0.77 | 3.43% | 3.98x |
|
NBY
NovaBay Pharmaceuticals
|
$0.76 | $7.30 | $3.7M | -- | $0.00 | 0% | 0.08x |
|
PYXS
Pyxis Oncology
|
$1.53 | $8.83 | $91M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
-- | -1.577 | -- | 2.97x |
|
BMRA
Biomerica
|
-- | 2.885 | -- | 2.03x |
|
CDTX
Cidara Therapeutics
|
-- | 2.880 | -- | 4.21x |
|
GILD
Gilead Sciences
|
55.72% | 0.436 | 22.27% | 0.82x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.365 | 1.51% | 0.75x |
|
PYXS
Pyxis Oncology
|
-- | -0.170 | -- | 11.67x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOOK
HOOKIPA Pharma
|
-- | -$15.4M | -48.13% | -48.48% | -294.3% | -$17.5M |
|
BMRA
Biomerica
|
$289K | -$1.4M | -77.23% | -77.23% | -75.71% | -$1.3M |
|
CDTX
Cidara Therapeutics
|
$6.9M | -$17.4M | -443.37% | -443.37% | -3675.83% | -$36.8M |
|
GILD
Gilead Sciences
|
$6B | $3.1B | 0.29% | 0.64% | 15.83% | $4.2B |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
PYXS
Pyxis Oncology
|
-- | -$23.8M | -- | -- | -34.72% | -$14.7M |
HOOKIPA Pharma vs. Competitors
-
Which has Higher Returns HOOK or BMRA?
Biomerica has a net margin of -294.3% compared to HOOKIPA Pharma's net margin of -72.83%. HOOKIPA Pharma's return on equity of -48.48% beat Biomerica's return on equity of -77.23%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.10 $71.8M BMRABiomerica15.99% -$0.08 $5.3M -
What do Analysts Say About HOOK or BMRA?
HOOKIPA Pharma has a consensus price target of $16.33, signalling upside risk potential of 817.6%. On the other hand Biomerica has an analysts' consensus of -- which suggests that it could grow by 3948.58%. Given that Biomerica has higher upside potential than HOOKIPA Pharma, analysts believe Biomerica is more attractive than HOOKIPA Pharma.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma1 2 0 BMRABiomerica0 0 0 -
Is HOOK or BMRA More Risky?
HOOKIPA Pharma has a beta of 0.713, which suggesting that the stock is 28.74% less volatile than S&P 500. In comparison Biomerica has a beta of -1.042, suggesting its less volatile than the S&P 500 by 204.193%.
-
Which is a Better Dividend Stock HOOK or BMRA?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biomerica offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Biomerica pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or BMRA?
HOOKIPA Pharma quarterly revenues are $4.7M, which are larger than Biomerica quarterly revenues of $1.8M. HOOKIPA Pharma's net income of -$13.8M is lower than Biomerica's net income of -$1.3M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Biomerica's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 0.44x versus 0.98x for Biomerica. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma0.44x -- $4.7M -$13.8M BMRABiomerica0.98x -- $1.8M -$1.3M
-
Which has Higher Returns HOOK or CDTX?
Cidara Therapeutics has a net margin of -294.3% compared to HOOKIPA Pharma's net margin of -30201.66%. HOOKIPA Pharma's return on equity of -48.48% beat Cidara Therapeutics's return on equity of -443.37%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.10 $71.8M CDTXCidara Therapeutics81.53% -$2.45 $130.9M -
What do Analysts Say About HOOK or CDTX?
HOOKIPA Pharma has a consensus price target of $16.33, signalling upside risk potential of 817.6%. On the other hand Cidara Therapeutics has an analysts' consensus of $31.50 which suggests that it could grow by 48.66%. Given that HOOKIPA Pharma has higher upside potential than Cidara Therapeutics, analysts believe HOOKIPA Pharma is more attractive than Cidara Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma1 2 0 CDTXCidara Therapeutics2 0 0 -
Is HOOK or CDTX More Risky?
HOOKIPA Pharma has a beta of 0.713, which suggesting that the stock is 28.74% less volatile than S&P 500. In comparison Cidara Therapeutics has a beta of 0.983, suggesting its less volatile than the S&P 500 by 1.698%.
-
Which is a Better Dividend Stock HOOK or CDTX?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Cidara Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or CDTX?
HOOKIPA Pharma quarterly revenues are $4.7M, which are larger than Cidara Therapeutics quarterly revenues of $302K. HOOKIPA Pharma's net income of -$13.8M is higher than Cidara Therapeutics's net income of -$16M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Cidara Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 0.44x versus 1.74x for Cidara Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma0.44x -- $4.7M -$13.8M CDTXCidara Therapeutics1.74x -- $302K -$16M
-
Which has Higher Returns HOOK or GILD?
Gilead Sciences has a net margin of -294.3% compared to HOOKIPA Pharma's net margin of 16.61%. HOOKIPA Pharma's return on equity of -48.48% beat Gilead Sciences's return on equity of 0.64%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.10 $71.8M GILDGilead Sciences79.14% $1.00 $41.6B -
What do Analysts Say About HOOK or GILD?
HOOKIPA Pharma has a consensus price target of $16.33, signalling upside risk potential of 817.6%. On the other hand Gilead Sciences has an analysts' consensus of $99.96 which suggests that it could grow by 11.14%. Given that HOOKIPA Pharma has higher upside potential than Gilead Sciences, analysts believe HOOKIPA Pharma is more attractive than Gilead Sciences.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma1 2 0 GILDGilead Sciences13 11 0 -
Is HOOK or GILD More Risky?
HOOKIPA Pharma has a beta of 0.713, which suggesting that the stock is 28.74% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.179, suggesting its less volatile than the S&P 500 by 82.12%.
-
Which is a Better Dividend Stock HOOK or GILD?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 3.43% to investors and pays a quarterly dividend of $0.77 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Gilead Sciences pays out 67.24% of its earnings as a dividend. Gilead Sciences's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOOK or GILD?
HOOKIPA Pharma quarterly revenues are $4.7M, which are smaller than Gilead Sciences quarterly revenues of $7.5B. HOOKIPA Pharma's net income of -$13.8M is lower than Gilead Sciences's net income of $1.3B. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 999.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 0.44x versus 3.98x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma0.44x -- $4.7M -$13.8M GILDGilead Sciences3.98x 999.33x $7.5B $1.3B
-
Which has Higher Returns HOOK or NBY?
NovaBay Pharmaceuticals has a net margin of -294.3% compared to HOOKIPA Pharma's net margin of -49.65%. HOOKIPA Pharma's return on equity of -48.48% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.10 $71.8M NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About HOOK or NBY?
HOOKIPA Pharma has a consensus price target of $16.33, signalling upside risk potential of 817.6%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 393.38%. Given that HOOKIPA Pharma has higher upside potential than NovaBay Pharmaceuticals, analysts believe HOOKIPA Pharma is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma1 2 0 NBYNovaBay Pharmaceuticals2 0 0 -
Is HOOK or NBY More Risky?
HOOKIPA Pharma has a beta of 0.713, which suggesting that the stock is 28.74% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.
-
Which is a Better Dividend Stock HOOK or NBY?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or NBY?
HOOKIPA Pharma quarterly revenues are $4.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. HOOKIPA Pharma's net income of -$13.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 0.44x versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma0.44x -- $4.7M -$13.8M NBYNovaBay Pharmaceuticals0.08x -- $2.4M -$1.2M
-
Which has Higher Returns HOOK or PYXS?
Pyxis Oncology has a net margin of -294.3% compared to HOOKIPA Pharma's net margin of -20.17%. HOOKIPA Pharma's return on equity of -48.48% beat Pyxis Oncology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOOKHOOKIPA Pharma-- -$1.10 $71.8M PYXSPyxis Oncology97.06% -$0.35 $184.2M -
What do Analysts Say About HOOK or PYXS?
HOOKIPA Pharma has a consensus price target of $16.33, signalling upside risk potential of 817.6%. On the other hand Pyxis Oncology has an analysts' consensus of $8.83 which suggests that it could grow by 477.34%. Given that HOOKIPA Pharma has higher upside potential than Pyxis Oncology, analysts believe HOOKIPA Pharma is more attractive than Pyxis Oncology.
Company Buy Ratings Hold Ratings Sell Ratings HOOKHOOKIPA Pharma1 2 0 PYXSPyxis Oncology5 1 0 -
Is HOOK or PYXS More Risky?
HOOKIPA Pharma has a beta of 0.713, which suggesting that the stock is 28.74% less volatile than S&P 500. In comparison Pyxis Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HOOK or PYXS?
HOOKIPA Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOOKIPA Pharma pays -- of its earnings as a dividend. Pyxis Oncology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios HOOK or PYXS?
HOOKIPA Pharma quarterly revenues are $4.7M, which are smaller than Pyxis Oncology quarterly revenues of $16.1M. HOOKIPA Pharma's net income of -$13.8M is higher than Pyxis Oncology's net income of -$21.2M. Notably, HOOKIPA Pharma's price-to-earnings ratio is -- while Pyxis Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOOKIPA Pharma is 0.44x versus -- for Pyxis Oncology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOOKHOOKIPA Pharma0.44x -- $4.7M -$13.8M PYXSPyxis Oncology-- -- $16.1M -$21.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Is American Tower Stock Undervalued?
The market action of late has been nothing short of…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is up 34.08% over the past day.
Buy
78
DJTWW alert for Jan 14
Trump Media & Technology Group [DJTWW] is up 31.44% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 26.23% over the past day.
